
---
title: '给受体上_双保险_，精准制导癌细胞：研究团队开发新型受体，有效插入T细胞，精准探测并消灭癌细胞'
categories: 
 - 新媒体
 - 果壳网
 - 科学人
headimg: 'https://3-im.guokr.com/ghzcpgWZ7P0I-BEUv2T_bS3R3fLGraHALzofUYVuuaw4BAAAmAEAAFBO.png?imageView2/1/w/555/h/209'
author: 果壳网
comments: false
date: Mon, 16 May 2022 07:30:13 GMT
thumbnail: 'https://3-im.guokr.com/ghzcpgWZ7P0I-BEUv2T_bS3R3fLGraHALzofUYVuuaw4BAAAmAEAAFBO.png?imageView2/1/w/555/h/209'
---

<div>   
<section style="line-height: 2;padding-right: 8px;padding-left: 8px;color: rgb(62, 62, 62);box-sizing: border-box;font-size: 16px;"><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;">近年来，基于基因工程免疫细胞疗法成为一种有望治疗癌症的方法。与传统药物相比，基因工程免疫细胞能更加准确地探测和消灭癌细胞。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">尽管未来充满希望，免疫细胞疗法仍然存在许多限制，包括其毒性和攻击健康细胞的可能性。此外，对于如何改造现有的免疫细胞疗法以扩大其应用范围或更好地控制其活性，科学家们仍没有很好的解决方法。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;">为了攻克这个难题，格拉德斯通研究所和加州大学旧金山分校医学院的研究人员们对用于构建细胞疗法的分子组件进行了系统的分析。他们的论文发表于《细胞》杂志上，这篇文章提供了全面的指南，<strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">用于设计具有更高特异性和安全性的治疗性T细胞，以及最终定制基于免疫细胞疗法的治疗方案</span></strong>。</p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img class="rich_pages wxw-img" data-ratio="0.3777778" data-type="png" data-w="1080" style="vertical-align: middle;box-sizing: border-box;height: auto !important;" data-src="https://3-im.guokr.com/ghzcpgWZ7P0I-BEUv2T_bS3R3fLGraHALzofUYVuuaw4BAAAmAEAAFBO.png" src="https://3-im.guokr.com/ghzcpgWZ7P0I-BEUv2T_bS3R3fLGraHALzofUYVuuaw4BAAAmAEAAFBO.png?imageView2/1/w/555/h/209" referrerpolicy="no-referrer"></section></section><section style="font-size: 12px;line-height: 1.4;color: rgb(204, 204, 204);box-sizing: border-box;" powered-by="xiumi.us"><p style="text-align: center;white-space: normal;box-sizing: border-box;">论文截图</p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">该研究的通讯作者，加州大学旧金山分校微生物和免疫学系副教授Kole Roybalp说：“我们已经制定了一些准则，这些准则应极大地促进治疗性免疫细胞的基因工程改造，使其具有比以前<strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">更高的灵敏性、准确性和安全性</span></strong>。”Kole Roybal教授来自加州大学旧金山分校微生物和免疫学系，是格拉德斯通-加州大学旧金山分校基因免疫学研究所的核心成员，同时也是帕克癌症免疫治疗研究所的研究员。他解释道：“我们的工作将为生物医学研究人员提供一个工具包，用于指导一系列基于免疫细胞的疗法达到预期目标，并用于规划其治疗。”</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="margin-top: 10px;margin-bottom: 10px;padding-right: 6px;padding-bottom: 6px;text-align: center;box-sizing: border-box;" powered-by="xiumi.us"><section style="padding-top: 6px;display: inline-block;background-color: rgba(117, 222, 239, 0.45);box-sizing: border-box;"><section style="margin-right: -6px;margin-bottom: -6px;margin-left: 6px;background-color: rgb(12, 31, 56);color: rgb(255, 255, 255);padding-right: 10px;padding-left: 10px;font-size: 18px;letter-spacing: 1px;line-height: 2.5;box-sizing: border-box;"><p style="box-sizing: border-box;">制造更好的受体</p></section></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">受体是绝大多数免疫细胞疗法的核心，它们是穿越细胞内外膜的大分子蛋白质。在细胞膜外侧，它们能识别一个特定的目标（例如癌细胞表面的一个蛋白质），在细胞膜内侧，它们将告诉细胞识别这个目标后该做什么。设计治疗性细胞的一种方法是在一种细胞——通常是免疫细胞T细胞——中插入由已知受体的片段组装而成的复合受体。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">这种方法也被用来制造CAR-T细胞，事实证明，这种细胞对治疗某些类型的血癌非常有效。CAR-T细胞拥有一个"嵌合抗原受体"（CAR），该受体通过基因重组技术将特异性受体与T细胞嵌合到了一起。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">从不同的细胞骨架开始，Roybal起先设计了一种叫做<strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">synNotch</span></strong>的受体，它可以引导T细胞更好地识别和杀死实体肿瘤。自从开始这个早期研究以来，Roybal的实验室已经展示了synNotch如何与CARs 联合用来开发治疗卵巢癌和间皮瘤的第二代细胞疗法。synNotch受体使科学家能够精确控制治疗性T细胞的激活时间和部位。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">“这种智能细胞疗法可以精确地在疾病发生的部位释放出强大的治疗活性，提高疗效，减少毒副作用的发生，而这些毒副作用甚至有可能威胁到患者生命。”Roybal说。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">然而，初代synNotch受体很难在基于人类细胞的治疗中起作用。首先，它体积庞大，很难插入人体细胞。另一方面，它的一些基因片段来自小鼠、酵母和病毒而不是人类受体，一旦将其引入病人体内，就会诱发免疫排斥反应。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">为了能从synNotch受体中保留和移除某些片段，同时不失去其预期的治疗功能，Roybal团队系统性地交换了该受体的各个片段。在将修改后的受体插入人类T细胞中后，科学家们测试了它们识别预定目标和激活预期反应的能力。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">这项研究的第一作者、Roybal实验室的博士后研究员Raymond Liu博士说：“研究已知受体的不同片段究竟如何起作用，是一项具有挑战性但充满乐趣的实验，这样我们就可以把这些片段拆开，用全新的方法把它们重新组合起来，以满足我们的设计规范。”</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">最后，研究小组制作了一系列他们称之为<strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">SNIPRs</span></strong>的受体，这些受体足够小，可以低成本地被嵌入人体细胞内。它们也完全由人类受体片段制成，可以检测并响应少量的目标细胞。此外，可以调整SNIPRs的活性，使携带它们的细胞不仅可以杀死目标细胞，还可以将特定的分子送到肿瘤的准确部位。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">Roybal实验室的博士研究生、这项研究的另一位第一作者Iowis Zhu说：“理解受体设计的规则后，我们能够构建更有效、也更适合临床应用的受体。”</p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img class="rich_pages wxw-img" data-ratio="1" data-type="jpeg" data-w="996" style="vertical-align: middle;box-sizing: border-box;height: auto !important;" data-src="https://3-im.guokr.com/F_D6gckN3_sST6gbPjyWm2OSKkZ652juSWKxEG5MlxnkAwAA5AMAAEpQ.jpg" src="https://3-im.guokr.com/F_D6gckN3_sST6gbPjyWm2OSKkZ652juSWKxEG5MlxnkAwAA5AMAAEpQ.jpg?imageView2/1/w/555/h/555" referrerpolicy="no-referrer"></section></section><section style="margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="font-size: 12px;line-height: 1.4;color: rgb(204, 204, 204);text-align: center;box-sizing: border-box;"><p style="box-sizing: border-box;">SNIPRs受体应用流程｜参考文献[1]</p></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="margin-top: 10px;margin-bottom: 10px;padding-right: 6px;padding-bottom: 6px;text-align: center;box-sizing: border-box;" powered-by="xiumi.us"><section style="padding-top: 6px;display: inline-block;background-color: rgba(117, 222, 239, 0.45);box-sizing: border-box;"><section style="margin-right: -6px;margin-bottom: -6px;margin-left: 6px;background-color: rgb(12, 31, 56);color: rgb(255, 255, 255);padding-right: 10px;padding-left: 10px;font-size: 18px;letter-spacing: 1px;line-height: 2.5;box-sizing: border-box;"><p style="box-sizing: border-box;">下一代细胞治疗平台</p></section></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">接下来，研究人员评估了这些优化后的受体在白血病、间皮瘤和卵巢癌小鼠模型中清除肿瘤的能力。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">为了减少杀死正常细胞，研究人员们将一种设计用于识别肿瘤上一个分子的SNIPR受体和另一个肿瘤分子的CAR受体相结合。此外，他们使CAR受体的产生依赖于SNIPR受体的激活。这样，只有同时携带synNotch和CAR受体目标的细胞才会被杀死，而只携带一个目标的细胞则不会。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">在他们测试的三种癌症类型中，使用两种受体能够比单独使用任何一种受体更有选择性地消灭癌细胞，显著表明这种方法有望减少细胞疗法的靶向毒性。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">目前，不论是在学术领域，还是在Roybal联合创立的阿森纳生物公司中(Arsenal Bio)，基于SNIPRs的细胞疗法正被优化用于治疗卵巢癌、肾癌、前列腺癌和脑胶质母细胞瘤。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">并且，基于SNIPR的细胞疗法可能不仅仅可用于癌症治疗。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">这种受体系统也可以通过增强免疫细胞的抗炎活性来治疗自身免疫性疾病。此外，也可以将SNIPRs插入靶向干细胞或其他类型的细胞，来探测组织损伤并诱导组织修复或逆转组织纤维化。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">“与传统的小分子和生物制品相比，基因工程细胞具有更有效的治疗作用。”Roybal说。“我们希望我们的新受体可以提供一个技术平台，使科学家和临床医生能够设计更安全、更有针对性和更有效的细胞疗法，以用于治疗癌症和许多其他疾病。”</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="display: flex;align-items: center;box-sizing: border-box;"><section style="flex: 1 1 auto;height: 1px;background-color: rgb(204, 204, 204);box-sizing: border-box;"><section><svg viewBox="0 0 1 1" style="float:left;line-height:0;width:0;vertical-align:top;"/></section></section><section style="flex: 0 1 auto;box-sizing: border-box;"><section opera-tn-ra-cell="_$.pages:0.layers:0.comps:14.col1" style="padding-right: 15px;padding-left: 15px;box-sizing: border-box;"><section style="text-align: center;color: rgb(205, 204, 204);font-size: 14px;line-height: 1.61;box-sizing: border-box;" powered-by="xiumi.us"><p style="box-sizing: border-box;">参考文献<br style="box-sizing: border-box;"></p></section></section></section><section style="flex: 1 1 auto;height: 1px;transform: matrix(-1, 0, 0, 1, 0, 0);-webkit-transform: matrix(-1, 0, 0, 1, 0, 0);-moz-transform: matrix(-1, 0, 0, 1, 0, 0);-o-transform: matrix(-1, 0, 0, 1, 0, 0);background-color: rgb(204, 204, 204);box-sizing: border-box;"><section><svg viewBox="0 0 1 1" style="float:left;line-height:0;width:0;vertical-align:top;"/></section></section></section></section><section style="line-height: 1.61;color: rgb(205, 204, 204);box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><span style="font-size: 12px;box-sizing: border-box;">[1] Modular design of synthetic receptors for programmed gene regulation in cell therapies</span></p><p style="white-space: normal;box-sizing: border-box;"><span style="font-size: 12px;box-sizing: border-box;">Zhu, Iowis., Raymond Liu., Julie M. Garcia., Bin Liu., Ahmad S. Khalil., Kole T. Roybal. Cell, Volume 185, Issue 8, 1431 - 1443.e16.</span></p><p style="white-space: normal;box-sizing: border-box;"><span style="font-size: 12px;box-sizing: border-box;">DOI:https://doi.org/10.1016/j.cell.2022.03.023</span></p><p style="white-space: normal;box-sizing: border-box;"><span style="font-size: 12px;box-sizing: border-box;">[2] https://medicalxpress.com/news/2022-04-toolkit-safe-efficient-therapeutic-cells.html</span></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="font-size: 12px;color: rgb(120, 120, 120);line-height: 2;letter-spacing: 0px;box-sizing: border-box;" powered-by="xiumi.us"><p style="text-align: center;white-space: normal;box-sizing: border-box;"><span style="color:#cccccc;box-sizing: border-box;">编译：四七</span></p><p style="text-align: center;white-space: normal;box-sizing: border-box;"><span style="color:#cccccc;box-sizing: border-box;">编辑：酥鱼</span></p><p style="text-align: center;white-space: normal;box-sizing: border-box;"><span style="color:#cccccc;box-sizing: border-box;">排版：尹宁流</span></p><p style="text-align: center;white-space: normal;box-sizing: border-box;"><span style="color:#cccccc;box-sizing: border-box;">题图：嵌合抗原受体T细胞疗法（CAR）过程示意图</span></p><p style="text-align: center;white-space: normal;box-sizing: border-box;"><span style="color:#cccccc;box-sizing: border-box;">题图来源：Wikimedia Commons，Reyasingh56 / CC BY-SA 4.0（https://creativecommons.org/licenses/by-sa/4.0）</span></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><section style="margin-right: 0%;margin-bottom: 10px;margin-left: 0%;text-align: left;justify-content: flex-start;display: flex;flex-flow: row nowrap;box-sizing: border-box;"><section style="display: inline-block;width: 100%;vertical-align: top;border-left: 4px solid rgb(5, 24, 86);border-bottom-left-radius: 0px;background-color: rgba(117, 222, 239, 0.05);padding: 24px;align-self: flex-start;flex: 0 0 auto;box-sizing: border-box;"><section style="color: rgb(12, 31, 56);text-align: justify;box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;">研究团队</strong></p></section><section style="text-align: justify;box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="font-size: 14px;text-align: justify;box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">通讯作者</span></strong> Kole T. Roybal：副教授，微生物和免疫学系，加州大学旧金山分校医学院；格拉德斯通基因免疫学研究所的核心成员，帕克癌症免疫治疗研究所研究员。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">课题组网址</span></strong>https://roybal-lab.org/</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">（共同）第一作者</span></strong>  Raymond Liu：博士后研究员，微生物与免疫学系，加州大学旧金山分校医学院。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">（共同）第一作者</span></strong> Iowis Zhu：博士研究员，微生物与免疫学系，加州大学旧金山分校医学院。</p></section></section></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><section style="margin-right: 0%;margin-bottom: 10px;margin-left: 0%;text-align: left;justify-content: flex-start;display: flex;flex-flow: row nowrap;box-sizing: border-box;"><section style="display: inline-block;width: 100%;vertical-align: top;border-left: 4px solid rgb(5, 24, 86);border-bottom-left-radius: 0px;background-color: rgba(117, 222, 239, 0.05);padding: 24px;align-self: flex-start;flex: 0 0 auto;box-sizing: border-box;"><section style="color: rgb(12, 31, 56);text-align: justify;box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;">论文信息</strong></p></section><section style="text-align: justify;box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="font-size: 14px;text-align: justify;box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">发布期刊</span></strong> 《细胞》 <em style="box-sizing: border-box;">Cell </em><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;"><br></p><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">发布时间</span></strong> 2022年4月14日</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">论文标题</span></strong><em style="box-sizing: border-box;">Modular design of synthetic receptors for programmed gene regulation in cell therapies</em></p><p style="text-align: left;white-space: normal;box-sizing: border-box;">（DOI：https://doi.org/10.1016/j.cell.2022.03.023）</p><p style="white-space: normal;box-sizing: border-box;"><br></p><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">文章领域</span></strong> 细胞免疫疗法，基因工程</p></section></section></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br></p><section style="outline: 0px;max-width: 100%;box-sizing: border-box;line-height: 2.25;letter-spacing: 1.5px;font-size: 15px;visibility: visible;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="margin-bottom: 0em;padding-right: 8px;padding-left: 8px;outline: 0px;max-width: 100%;box-sizing: border-box;line-height: 2;font-size: 16px;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;justify-content: center;overflow-wrap: break-word !important;"><section style="padding-top: 15px;outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 645px;vertical-align: top;border-style: solid;border-width: 1px;border-color: rgb(12, 31, 56);height: auto;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="padding-right: 8px;padding-left: 8px;outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;color: rgb(62, 62, 62);overflow-wrap: break-word !important;"><p style="margin-bottom: 15px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: justify;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;">未来光锥加速器是果壳硬科技发起的早期科技创业加速器，为科学家创业提供从公司注册、知识产权，到融资需求、团队组建等不同阶段的方案建议。加速科技成果从实验室到市场的转化，加速一部分科学家迭代成为CEO。</span></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: justify;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;">果壳团队有着长达12年为科学家服务的经验，我们始终站在科学家的视角出谋划策，做科创者的好朋友。如果您正打算创办一家科技企业，无论是找钱、找人、找资源，还是找订单，都欢迎与未来光锥团队聊聊。您可发送bp或其他项目资料到<strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(12, 31, 56);overflow-wrap: break-word !important;">wlgz@guokr.com</span></strong>，并留下联系方式，或添加果壳硬科技企业微信，私信沟通。</span></p></section></section><section powered-by="xiumi.us" style="margin-top: 20px;outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;vertical-align: middle;display: inline-block;line-height: 0;width: 257.199px;height: auto;overflow-wrap: break-word !important;"><img class="rich_pages wxw-img" data-ratio="1.004065" data-type="png" data-w="492" style="outline: 0px;box-sizing: border-box;vertical-align: middle;overflow-wrap: break-word !important;visibility: visible !important;width: 257.199px !important;height: auto !important;" data-src="https://3-im.guokr.com/6c-6Pym-LLXKr15YwPF4lK0vDWofBx-G6sEKlWwzA2fsAQAA7gEAAFBO.png" src="https://3-im.guokr.com/6c-6Pym-LLXKr15YwPF4lK0vDWofBx-G6sEKlWwzA2fsAQAA7gEAAFBO.png" referrerpolicy="no-referrer"></section></section><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: right;justify-content: flex-end;display: flex;flex-flow: row nowrap;transform: translate3d(15px, 0px, 0px);overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;vertical-align: bottom;width: auto;flex: 100 100 0%;height: auto;align-self: flex-end;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: justify;font-size: 12px;overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><br style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"></p></section></section><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;vertical-align: bottom;width: auto;min-width: 10%;flex: 0 0 auto;height: auto;align-self: flex-end;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="margin-bottom: -5px;outline: 0px;max-width: 100%;box-sizing: border-box;transform: scale(0.77);transform-origin: right top;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;justify-content: flex-end;transform: translate3d(21px, 0px, 0px);overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(12, 31, 56);overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;">✦</p></section></section></section></section><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;vertical-align: bottom;width: auto;min-width: 10%;flex: 0 0 auto;height: auto;align-self: flex-end;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="margin-bottom: 12px;outline: 0px;max-width: 100%;box-sizing: border-box;justify-content: flex-end;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(12, 31, 56);overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;">✦</p></section></section></section></section></section></section></section></section></section></section></section><p><br></p><p><br></p></section><section style="border-bottom: 2px solid rgb(15, 97, 164);text-align: left;font-size: 14px;box-sizing: border-box;" powered-by="xiumi.us"><p style="box-sizing: border-box;">点击阅读原文即可查看原论文</p></section><section style="margin-left: 8%;margin-right: 8%;line-height: 1.1em;box-sizing: border-box;" powered-by="xiumi.us"><section style="width: 0px;display: inline-block;vertical-align: top;border-top: 1em solid rgb(15, 97, 164);border-left: 0.8em solid transparent !important;border-right: 0.8em solid transparent !important;box-sizing: border-box;"><section><svg viewBox="0 0 1 1" style="float:left;line-height:0;width:0;vertical-align:top;"/></section></section></section></section><p><br></p>
            
</div>
            